LGA
OCUL icon

Lebenthal Global Advisors’s Ocular Therapeutix OCUL Stock Holding History

Lebenthal Global Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-830
Closed -$17K – 407
2020
Q4 		$17K Buy
+830
New +$12.3K 0.01% 392

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lebenthal Global Advisors's OCUL Position: Q1 2021 in Review

Lebenthal Global Advisors sold out of Ocular Therapeutix (OCUL) in Q1 2021, closing a stake of 830 shares — an estimated $17K sold.

Lebenthal Global Advisors first reported a position in OCUL in Q4 2020 and held it in 1 quarter. The position peaked at $17K in Q4 2020. 154 funds tracked by Wall St. Rank hold OCUL as of Q1 2021.

  • Lebenthal Global Advisors reported no remaining Ocular Therapeutix position as of Q1 2021 after selling out during the quarter.
  • Lebenthal Global Advisors sold 830 Ocular Therapeutix shares in Q1 2021, an estimated $17K.
  • Lebenthal Global Advisors first reported a position in Ocular Therapeutix in Q4 2020 and held it in 1 quarter.
  • Lebenthal Global Advisors's Ocular Therapeutix position peaked at $17K in Q4 2020.
  • 154 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2021.

Based on Lebenthal Global Advisors's 13F filing for Q1 2021, filed 7 May 2021.